Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,451 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 21,451 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001579003-26-000002 · form4-01062026_050108.xml · derivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001579003-26-000002 · form4-01062026_050108.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,451 F1 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · derivative · entry 18 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,900 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,299 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · derivative · entry 17 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,299 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 700 | $85.32 | $59,724.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 14 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,451 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.60 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,238 | $84.47 | $104,573.86 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 13 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,151 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,502 | $83.38 | $291,996.76 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 12 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,389 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.00 to $83.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,460 | $82.58 | $203,146.80 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 11 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,891 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.00 to $82.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,900 | $18.01 | $142,279.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 10 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 400 | $85.24 | $34,096.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 9 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,451 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.14 to $85.34 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,125 | $84.45 | $95,006.25 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 8 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,851 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,510 | $83.93 | $210,664.30 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 7 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,976 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.00 to $83.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,264 | $82.63 | $187,074.32 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 6 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,486 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.00 to $82.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,299 | $11.23 | $70,737.77 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 5 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,100 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · derivative · entry 16 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 6,100 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,701 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · derivative · entry 15 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,299 Underlying: Common Stock · 5,701 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,100 | $80.15 | $488,915.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 4 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,451 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,100 | $18.01 | $109,861.00 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 3 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,701 | $80.13 | $456,821.13 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,451 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 5,701 | $11.23 | $64,022.23 |
DisclosureSEC source: 0001579003-25-000005 · form4-11262025_051101.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025 Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001579003-25-000003 · form4-10072025_051005.xml · derivative · entry 3 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 12,000 | $65.00 | $780,000.00 |
DisclosureSEC source: 0001579003-25-000003 · form4-10072025_051005.xml · nonDerivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,451 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 12,000 | $30.86 | $370,320.00 |
DisclosureSEC source: 0001579003-25-000003 · form4-10072025_051005.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025. Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,667 | $50.15 | $83,600.05 |
DisclosureSEC source: 0001415889-25-023430 · form4-09022025_050901.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,451 Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,230 | $51.52 | $63,369.60 |
DisclosureSEC source: 0001415889-25-007250 · form4-03062025_050301.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,118 F1 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.50 to $51.54 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001023 · form4-01072025_050118.xml · derivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001023 · form4-01072025_050118.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,348 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004103 · form4-02162024_040229.xml · derivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-14 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004103 · form4-02162024_040229.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,348 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $27.05 Strike: $27.05 | $270,500.00 |
DisclosureSEC source: 0001415889-24-001753 · form4-01242024_090138.xml · derivative · entry 3 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,000 | $27.38 | $273,804.00 |
DisclosureSEC source: 0001415889-24-001753 · form4-01242024_090138.xml · nonDerivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,348 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $27.15 to $27.90 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $27.05 | $270,500.00 |
DisclosureSEC source: 0001415889-24-001753 · form4-01242024_090138.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,000 | $10.85 Strike: $10.85 | $249,550.00 |
DisclosureSEC source: 0001415889-23-007888 · form4-05122023_080552.xml · derivative · entry 5 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,000 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 11, 2022. F5 · derivative.exercise_date: Currently exercisable. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,100 | $56.99 | $62,686.91 |
DisclosureSEC source: 0001415889-23-007888 · form4-05122023_080552.xml · nonDerivative · entry 4 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,348 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 11, 2022. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.85 to $57.15 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,860 | $56.35 | $161,169.01 |
DisclosureSEC source: 0001415889-23-007888 · form4-05122023_080552.xml · nonDerivative · entry 3 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,448 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 11, 2022. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.84 to $56.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 19,040 | $54.78 | $1,043,074.03 |
DisclosureSEC source: 0001415889-23-007888 · form4-05122023_080552.xml · nonDerivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,308 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 11, 2022. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.45 to $55.35 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 23,000 | $10.85 | $249,550.00 |
DisclosureSEC source: 0001415889-23-007888 · form4-05122023_080552.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 11, 2022. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000674 · form4-01092023_090152.xml · derivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000674 · form4-01092023_090152.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,348 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000390 · edgar.xml · derivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000390 · edgar.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,348 F1 · shares: Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000463 · edgar.xml · derivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000463 · edgar.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,148 F1 · shares: Restricted stock units ("RSUs") granted on January 6, 2021 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2021 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 6, 2022. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 20,000 | $10.85 Strike: $10.85 | $217,000.00 |
DisclosureSEC source: 0001179110-20-010869 · edgar.xml · derivative · entry 3 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 20,000 | $60.00 | $1,200,000.00 |
DisclosureSEC source: 0001179110-20-010869 · edgar.xml · nonDerivative · entry 2 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,498 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 20,000 | $10.85 | $217,000.00 |
DisclosureSEC source: 0001179110-20-010869 · edgar.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:35 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,000 | $51.29 | $256,450.00 |
DisclosureSEC source: 0001179110-20-010603 · edgar.xml · nonDerivative · entry 1 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,498 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2020. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 17,900 | $10.85 Strike: $10.85 | $194,215.00 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · derivative · entry 8 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 17,900 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. F5 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $52.16 | $5,216.00 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · nonDerivative · entry 6 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,498 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 20:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,653 | $51.41 | $496,299.34 |
DisclosureSEC source: 0001070081-20-000083 · wf-form4_158749998486296.xml · nonDerivative · entry 5 Jacobson Allan Steven · CIK 0001579003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,598 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.01 to $51.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.